MedTrace Logo

Effect of rhIL-11 in Patients With Thrombocytopenia for Childhood ALL

NCT02314273 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2014-12-11

No results posted yet for this study

Summary

The goal of this clinical research study is to find out if rhIL-11（Interleukin 11） may increase the platelet count in Childhood patients with acute lymphocytic leukemia (ALL) who develop low platelet counts while receiving standard CAT（cyclophosphamide+Cytosine arabinoside+mercaptopurine，7d） therapy.

Conditions

  • Pancytopenia Due to Chemotherapy

Interventions

DRUG

rhIL-11

patients receive rhIL-11(50 mcg/kg，subcutaneously)after standard chemotherapy，once a day for 10 days or until platelet count ≥80000/mL

Sponsors & Collaborators

  • Xiamen Amoytop Biotech Co., Ltd.

    collaborator INDUSTRY

  • Shanghai Children's Medical Center

    lead OTHER

Principal Investigators

  • Tang Jingyan, M.D. · Shanghai Children's Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-09-30
Primary Completion
2014-04-30
Completion
2014-04-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02314273 on ClinicalTrials.gov